title: Preparation and cellular targeting study of VEGF-conjugated PLGA nanoparticles.
abstract: Vascular endothelial growth factor receptor (VEGFR) is over-expressed on a variety of tumour cells and tumour neovasculature, and so becomes well-documented target for cancer treatment. This study was designed to evaluate the cellular targeting and anti-tumor potency of VEGF-conjugated nanoparticles (VEGF-NPs). The poly-lactic-co-glycolic acid nanoparticles were prepared using the emulsion-solvent evaporation method and the VEGF was conjugated on surface of nanoparticles by covalent coupling method. The obtained particles were found to be of spherical shape exhibiting a size of 710 nm and VEGF conjugation efficiency was 16.6%. The results in vitro test showed that VEGF-NPs were more associated to Human Umbilical Vein Endothelial Cells by binding to VEGFR. In vitro cell proliferation test, IC50 showed the superior antiproliferative activity of paclitaxel-loaded VEGF-NPs over unconjugated nanoparticles and native paclitaxel due to higher cellular association on tumour cells. So, the VEGF-NPs offer a promising active targeting carrier for tumour selective treatment.
authors.affiliation: a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China.
authors.forename: Yaling
authors.initials: Y
authors.lastname: Shi
authors.affiliation: a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China.
authors.forename: Mingyao
authors.initials: M
authors.lastname: Zhou
authors.affiliation: a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.affiliation: a School of Pharmacy, Health Science Center, Xi'an Jiaotong University , Xi'an , Shaanxi Province , RP China.
authors.forename: Wen
authors.initials: W
authors.lastname: Lu
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004337:Drug Carriers; D016503:Drug Delivery Systems; D061307:Human Umbilical Vein Endothelial Cells / Q000378:metabolism; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D017239:Paclitaxel / Q000494:pharmacology; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D042461:Vascular Endothelial Growth Factor A / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D042461:Vascular Endothelial Growth Factor A; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017239:Paclitaxel
keywords: Nanoparticles; paclitaxel; poly-lactic-co-glycolic acid; tumor targeting; vascular endothelial growth factor